Related Experiment Video

Updated: Jul 24, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
00:07

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.4K

Targeting cyclin D1 as a therapeutic approach for papillary thyroid carcinoma

Wei Cai1, Lin-Zhen Shu2, Ding-Jie Liu3

  • 1Department of Pathology, The Fourth Affiliated Hospital of Nanchang University, Nanchang, China.

Frontiers in Oncology
|July 10, 2023
PubMed

Insights

Cyclin D1 overexpression is common in papillary thyroid carcinoma (PTC). This review explores how abnormal cyclin D1 contributes to PTC development and discusses targeted therapies for this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Cyclin D1 acts as a mitogenic sensor, regulating cell cycle progression and interacting with transcription factors.
  • Dysregulation of Cyclin D1 is implicated in carcinogenesis.
  • Elevated Cyclin D1 expression is observed in papillary thyroid carcinoma (PTC).

Purpose of the Study:

  • To investigate the mechanisms of Cyclin D1 overexpression in PTC.
  • To elucidate the role of Cyclin D1 in PTC tumorigenesis.
  • To summarize therapeutic strategies targeting Cyclin D1 in PTC.

Main Methods:

  • Literature review of studies on Cyclin D1 in PTC.
  • Analysis of regulatory mechanisms of Cyclin D1 overexpression.
  • Examination of Cyclin D1's interactions with other cellular elements.

Main Results:

  • Cyclin D1 overexpression is a significant factor in PTC development.
  • Cyclin D1 influences key cellular processes like proliferation and apoptosis in PTC.
  • Various regulatory elements contribute to Cyclin D1's role in PTC.

Conclusions:

  • Understanding Cyclin D1 regulation in PTC is crucial for developing effective therapeutic strategies.
  • Targeting Cyclin D1 presents a promising avenue for novel PTC treatments.
  • Further research into Cyclin D1 mechanisms can lead to improved clinical outcomes for PTC patients.
Keywords:
CCND1cell cyclecyclin D1papillary thyroid carcinomapathogenesis

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

21.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K